Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05611229 · ClinicalTrials.gov registry record
Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,975
- Enrollment target
NCT05611229: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05611229 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,975 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05611229 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,975 participants
- Enrollment target
Study Summary
This was an observational study utilizing electronic health record (EHR)-derived data collected retrospectively during routine care of real-world patients with advanced melanoma from NOBLE (Novartis Braf+ meLanoma patients ObsErvational) dataset.
Primary Outcome
To describe treatment patterns among patients prescribed with TT versus IO in both the populations.
Interventions
- DRUG Pembrolizumab
- DRUG Nivolumab
- COMBINATION_PRODUCT Dabrafenib+Trametinib
- COMBINATION_PRODUCT Ipilimumab+Nivolumab
- COMBINATION_PRODUCT Vemurafenib+Cobimetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,975 participants |
| Start Date | 2020-06-16 |
| Est. Completion | 2021-12-03 |
What the finished NCT05611229 record still lists
NCT05611229 is an observational study that tracks outcomes without assigning an intervention. Its 1,975 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05611229 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05611229 about?
NCT05611229 is a clinical study titled "Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden". This was an observational study utilizing electronic health record (EHR)-derived data collected retrospectively during routine care of real-world patients with advanced melanoma from NOBLE (Novartis Braf+ meLanoma patients ObsErvational) dataset.
What is the current status of trial NCT05611229?
This trial is currently completed. The enrollment target is 1,975 participants. The study started on 2020-06-16. Estimated completion is 2021-12-03.
What interventions are being tested in trial NCT05611229?
The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Dabrafenib+Trametinib (COMBINATION_PRODUCT), Ipilimumab+Nivolumab (COMBINATION_PRODUCT), Vemurafenib+Cobimetinib (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05611229?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062394 · 1,980 participants · NA
Penn Medicine Healthy Heart
- NCT07321886 · 1,980 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- NCT04251052 · 1,956 participants · NA
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI